Uncovering the Pharmacology of GPR75: Role in Pulmonary Arterial Hypertension (360G-Wellcome-205862_Z_16_Z)

£99,881

Pulmonary arterial hypertension (PAH) is a devastating condition that if left untreated has an average life expectancy of less than three years from diagnosis. PAH is associated with proliferation of pulmonary artery smooth muscle cells (PASMC), which contributes to increased vascular resistance. The maintenance of the low vascular tone in the pulmonary circulation is dependent on the interaction of circulating and locally produced mediators, many of which act via G protein-coupled receptors (GPCRs). The accessibility of GPCRs on the plasma membrane, their tissue-selective distribution and role in regulating physiological functions make them excellent pharmacological targets. We used an "unbiased" approach (GPCR real-time-PCR arrays) to profile GPCR expression in PASMC isolated from control and PAH patients. Our data revealed that PAH-PASMC uniquely express an orphan GPCR (whose endogenous ligand has not yet been identified) compared to control-PASMC, namely GPR75. We aim to validate GPR75 as a novel target for PAH by uncovering its pharmacology and the functional significance and expression of receptor variants in PAH and by elucidating its physiological role in-vivo. Our hypothesis is that GPR75 is a key regulator of PASMC proliferation that characterizes PAH and is an exciting new target or genetic risk factor for the disease.

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 99881
Applicant Surname Murray
Approval Committee Science Seeds Advisory Panel
Award Date 2016-11-29T00:00:00+00:00
Financial Year 2016/17
Grant Programme: Title Seed Award in Science
Internal ID 205862/Z/16/Z
Lead Applicant Dr Fiona Murray
Partnership Value 99881
Planned Dates: End Date 2019-07-01T00:00:00+00:00
Planned Dates: Start Date 2017-03-01T00:00:00+00:00
Recipient Org: Country United Kingdom
Region Scotland